Literature DB >> 2556503

Alzheimer's disease: amyloid plaques in the cerebellum.

H Braak1, E Braak, J Bohl, W Lang.   

Abstract

Two specific silver-staining methods demonstrating either extracellular amyloid and/or precursors of amyloid or intraneuronal neurofibrillary changes were used to examine cerebellar pathology in cases of presenile and senile dementia of the Alzheimer type, cases of Down's syndrome, and non-demented controls. The sensitivity of the techniques permitted visualization of large numbers of amyloid deposits in the cerebellar cortex of demented individuals. Similarly large numbers of amyloid deposits were not found in the cerebella of non-demented individuals. Neurofibrillary changes were absent. The majority of amyloid plaques occurred in the molecular layer. Quite a number of these displayed large diameters extending from the upper surface down to the Purkinje cell layer. Within the granular layer and white matter the plaques were less frequently encountered and they were less voluminous than those of the molecular layer. The cerebellar amyloid plaques were morphologically different and could easily be distinguished from the cerebellar plaques found in transmissible spongiform encephalopathies.

Entities:  

Mesh:

Year:  1989        PMID: 2556503     DOI: 10.1016/0022-510x(89)90197-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  44 in total

1.  Senile plaques, amyloid beta-protein, and acetylcholinesterase fibres: laminar distributions in Alzheimer's disease striate cortex.

Authors:  T G Beach; E G McGeer
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Alzheimer's disease affects limbic nuclei of the thalamus.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

3.  Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.

Authors:  Alex E Roher; Chera L Maarouf; Tyler A Kokjohn; Charisse M Whiteside; Walter M Kalback; Geidy Serrano; Christine Belden; Carolyn Liebsack; Sandra A Jacobson; Marwan N Sabbagh; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

4.  The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis.

Authors:  G Cole; J W Neal; S K Singhrao; B Jasani; G R Newman
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.

Authors:  A D Snow; R T Sekiguchi; D Nochlin; R N Kalaria; K Kimata
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

6.  Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study.

Authors:  G Waldemar; P Bruhn; M Kristensen; A Johnsen; O B Paulson; N A Lassen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

7.  Microglia in cerebellar plaques in Alzheimer's disease.

Authors:  L A Mattiace; P Davies; S H Yen; D W Dickson
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 8.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Thymoquinone prevents β-amyloid neurotoxicity in primary cultured cerebellar granule neurons.

Authors:  Norsharina Ismail; Maznah Ismail; Musalmah Mazlan; Latiffah Abdul Latiff; Mustapha Umar Imam; Shahid Iqbal; Nur Hanisah Azmi; Siti Aisyah Abd Ghafar; Kim Wei Chan
Journal:  Cell Mol Neurobiol       Date:  2013-10-08       Impact factor: 5.046

10.  GNG13 Is a Potential Marker of the State of Health of Alzheimer's Disease Patients' Cerebellum.

Authors:  Cristina Sanfilippo; Giuseppe Musumeci; Maria Kazakova; Venera Mazzone; Paola Castrogiovanni; Rosa Imbesi; Michelino Di Rosa
Journal:  J Mol Neurosci       Date:  2020-10-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.